Brief: Mirum Pharmaceuticals Q2 Basic EPS USD -0.52
07/08/2024 21:01
Aug 07 (Reuters) - Mirum Pharmaceuticals Q2 operating expenses USD 102.107 million. * Q2 net income USD -24.638 million * Q2 product sales USD 77.76 million * Q2 operating income USD -24.232 million
Recent news on Mirum Pharmaceuticals
See all newsMirum Pharmaceuticals Q3 net product sales surge, outlook raised
Brief: Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva
Mirum climbs on positive late-stage trial results for liver disease drug
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX